Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Solid Tumors 2Neoplasms 2Liposarcoma 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tertiary Lymphoid Structures 1Solid Tumours 1Sarcoma 1Pancreatic Neoplasms 1Lung Neoplasms 1Histiocytoma, Malignant Fibrous 1Glioblastoma 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 19Ifosfamide 12Radiotherapy 11pembrolizumab 6Nivolumab 6Ipilimumab 6pazopanib 4Specimen Handling 4Radiation 4Gemcitabine 4Docetaxel 4CTLA-4 Antigen 4Biopsy 4Trabectedin 3Sunitinib 3Magnetic Resonance Spectroscopy 3pegfilgrastim 2liposomal doxorubicin 2cabozantinib 2brostallicin 2X-Rays 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Methotrexate 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Diathermy 2Cisplatin 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × brigimadlin × Clear all
NCT06370871 2024-07-17

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Boehringer Ingelheim

Phase 3 Withdrawn
Sarcoma

Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡